

ARV-393-101


ARV-393

NOW ENROLLING

A Phase 1 First-in-Human Study of ARV-393 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

ARV-393 is an investigational compound and is not approved for any use. Its safety and efficacy have not been established.

Trial Schema



This information is current as of May 2024.

Key Eligibility Criteria^a

Inclusion Criteria

- Men and women aged ≥ 18 years
- Relapsed/refractory mature B-cell NHL or histologically confirmed AITL that has recurred or progressed
 - ≥ 2 lines of prior therapy for patients with relapsed/refractory mature B-cell NHL
 - Progression or disease recurrence following standard of care therapy for patients with AITL
- ≥ 1 measurable lesion at study entry
- ECOG performance status of 0 or 1
- Freshly biopsied or archival tumor tissue available

Exclusion Criteria

- Prior allogeneic stem cell transplant
- Significant acute or chronic medical illness, including hypereosinophilic syndrome, active interstitial lung disease or pneumonitis, or active or uncontrolled infection

Summary of Outcome Measures

Primary Endpoints

- DLTs
- Safety and tolerability

Secondary Endpoints

- Pharmacokinetic parameters of ARV-393
- ORR,^b CRR,^c and DOR

^aThis is not the complete list of inclusion/exclusion criteria.

^bThe proportion of participants achieving a complete response or partial response according to the Lugano response criteria for NHL.

^cThe proportion of participants achieving a complete response according to the Lugano response criteria for NHL.

AE=adverse event; AITL=angioimmunoblastic T-cell lymphoma; CRR=complete response rate; DLT=dose-limiting toxicity; DOR=duration of response; ECOG=Eastern Cooperative Oncology Group; NHL=non-Hodgkin lymphoma; ORR=objective response rate.



For additional protocol details, please visit [www.ClinicalTrials.gov\(NCT06393738\)](http://www.ClinicalTrials.gov(NCT06393738))

ARVINAS